Pediatric patients who underwent BMT between Materials and methods Patients and data collection Therefore, the present studyĪimed to optimize the initial dosage of ciclosporin for safety andĮffectiveness in pediatric Chinese patients who underwent BMT based Pediatric renal transplants and Wilhelm et al ( 24) in patients receiving hematopoieticĪllogeneic stem cell transplants. Of ciclosporin in Chinese children with aplastic anemia, Fanta For example, Ni et al ( 21) established population pharmacokinetics Numerous studies have established population pharmacokinetics ofĬiclosporin. Used to collect sparse clinical data in order to model and simulateĪpproaches to assess dosing regimens in specific patients ( 16, 18). Population pharmacokinetics is a tool that can be Maintain the target concentration of the drug is crucial ( 19, 20). Identifying the optimal dose regimen of ciclosporin to achieve and Inter-individual pharmacokinetic variability ( 16-18). However, the therapeutic range is relatively narrow ( 15) and the drug exhibits wide Widely used as a treatment strategy for GVHD in pediatric patients Therefore, identifying a novel therapeutic strategy for GVHD isĬiclosporin, an immunosuppressant drug, has been Is characteristic of acute GVHD ( 11, 12). Resulting from an allogeneic interaction causes tissue injury that Morbidity and mortality following BMT and has an occurrence rate ofĪcute GVHD primarily occurs in the skin, intestines and liver However, the clinical application of BMT is limited byĪcute GVHD is a common complication which results in severe Patients with severe aplastic anemia ( 1), acute lymphoblastic leukemia ( 2), acute myeloid leukemia ( 3) and chronic myeloid leukemia ( 4, 5). The present study indicated that the optimal initial dose of ciclosporin for pediatric patients weighing 5‑30 kg who underwent BMT was 6 mg/kg/day split into 2 doses.īone marrow transplants (BMT) are used to treat The final population pharmacokinetic model indicated that body weight and days post‑transplant influenced the clearance of ciclosporin in pediatric patients who underwent BMT. Monte Carlo simulations were used to identify the optimal dose of ciclosporin. A non‑linear mixed‑effects model was used to analyze the clinical data of pediatric patients who underwent BMT between September 2016 and September 2019 at the Children's Hospital of Fudan University. The present study aimed to optimize the dosage of ciclosporin for safety and effectiveness based on population pharmacokinetics. Ciclosporin has been widely used for treating GVHD in pediatric patients who underwent BMT. However, the successful application of BMT is limited by graft‑vs.‑host disease (GVHD). Bone marrow transplants (BMT) are an established therapeutic strategy for patients with severe aplastic anemia, acute lymphoblastic leukemia, acute myeloid leukemia or chronic myeloid leukemia.